Skip Navigation
Search Menu
Find an Expert


Jordan J. Green, Ph.D.

Photo of Dr. Jordan J. Green, Ph.D.

Director, Biomaterials and Drug Delivery Laboratory

Associate Professor of Biomedical Engineering

Research Interests: Developing biomaterials; stem cells; nanobiotechnology to meet challenges in regenerative medicine; ophthalmology; cancer


Dr. Jordan J. Green is an assistant professor of biomedical engineering and ophthalmology at the Johns Hopkins University School of Medicine.

He also serves as the director of the Biomaterials and Drug Delivery Laboratory. He studies biomaterials, drug delivery, gene therapy, nanobiotechnology and cell engineering.

Dr. Green earned his Ph.D. in biological engineering from the Massachusetts Institute of Technology (MIT). He was awarded fellowships from both the National Science Foundation and the Whitaker International Fellows and Scholars Program for his graduate study.

He also holds a B.S. in biomedical engineering and chemical engineering from Carnegie Mellon University. As an undergraduate, he studied for a year at Imperial College London.

Dr. Green’s work has resulted in more than 20 academic papers, as well as patents in the areas of chemistry, biomaterials and drug delivery. His research has appeared in popular media outlets including The Boston Globe and more


  • Director, Biomaterials and Drug Delivery Laboratory
  • Associate Professor of Biomedical Engineering
  • Assistant Professor of Neurosurgery
  • Assistant Professor of Ophthalmology
  • Associate Professor of Oncology



  • B.S., Carnegie Mellon University (Pennsylvania) (2003)
  • Ph.D., Massachusetts Institute of Technology (Massachusetts) (2007)

Additional Training

Massachusetts Institute of Technology, Cambridge, MA, 2008, Chemical Engineering

Research & Publications

Research Summary

Dr. Green’s Biomaterials and Drug Delivery Laboratory (“Green Group”) focuses on the study of cellular engineering and in nanobiotechnology—particularly biomaterials, controlled drug delivery, stem cells, gene therapy and immunobioengineering.

The group examines the chemistry-biology-engineering interface to answer fundamental scientific questions – and to create innovative technologies and therapeutics that can directly benefit human health.

The goal is to better understand and control the therapeutic delivery of genetic material and drugs to cells.

His team is working to engineer biodegradable nanoparticles – often superior to viral delivery methods – that are efficiently delivered to be useful in drug release, gene therapy and new targeted treatments for cancer and eye diseases.

Current projects include: developing safe and effective biodegradable nanoparticles for DNA and siRNA delivery to treat cancer; developing polymeric microparticle-based biological treatments for age-related macular degeneration; designing biomimetic artificial antigen presenting cells for immunobioengineering; and enabling technologies for tissue engineering and regenerative medicine.

Lab Website: Green Group

Selected Publications

View all on Pubmed

Kozielski KL, Tzeng SY, Hurtado De Mendoza BA, Green JJ. "Bioreducible Cationic Polymer-Based Nanoparticles for Efficient and Environmentally Triggered Cytoplasmic siRNA Delivery to Primary Human Brain Cancer Cells." ACS Nano. 2014 Apr 3. [Epub ahead of print]

Bhise NS, Wahlin KJ, Zack DJ, Green JJ. "Evaluating the potential of poly(beta-amino ester) nanoparticles for reprogramming human fibroblasts to become induced pluripotent stem cells." Int J Nanomedicine. 2013;8:4641-58. doi: 10.2147/IJN.S53830. Epub 2013 Dec 4.

Kim J, Sunshine JC, Green JJ. "Differential Polymer Structure Tunes Mechanism of Cellular Uptake and Transfection Routes of Poly(β-amino ester) Polyplexes in Human Breast Cancer Cells." Bioconjug Chem. 2013 Dec 20. [Epub ahead of print]

Bishop CJ, Kim J, Green JJ. "Biomolecule Delivery to Engineer the Cellular Microenvironment for Regenerative Medicine." Ann Biomed Eng. 2013 Oct 30. [Epub ahead of print]

Sunshine JC, Perica K, Schneck JP, Green JJ. "Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells." Biomaterials. 2014 Jan;35(1):269-77. doi: 10.1016/j.biomaterials.2013.09.050. Epub 2013 Oct 5.

Activities & Honors


  • Rita Schaffer Young Investigator Award, Biomedical Engineering Society, 2011
Is this you? Edit Profile